ASPENBeiGeneEHAESMONSCLCPD-1Waldenström

Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma

 Volver  Ver
Phase 1/2 study of single‑agent Zanubrutinib in patients with relapsed / refractory marginal zone lymphoma
 POSTER   06/2020
 Download  Ver

Para obtener más información sobre esta publicación, por favor envíe una solicitud de información médica.

Rating

Rate this publication

Publicaciones relacionadas

Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies
Outcomes of Relapsed/Refractory MCL Patients Treated with Zanubrutinib Monotherapy in the Second Line and in Later Lines: A Pooled Analysis from 2 Studies
EHA 2020 & Library: selected abstracts on BeiGene products
EHA 2020 & Library: selected abstracts on BeiGene products
EHA25 - Virtual Satellite Symposium
EHA25 - Virtual Satellite Symposium
 Volver